Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 80 mikrog / 4,5 mikrog / inhalaatio - formoteroli ja budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

astrazeneca oy - budesonide, formoterol fumarate dihydrate - inhalaatiosumute, suspensio - 80 mikrog / 2.25 mikrog / inhalaatio - formoteroli ja budesonidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Suomi - suomi - Fimea (Suomen lääkevirasto)

paranova oy - budesonidum,formoteroli fumaras dihydricus - inhalaatiojauhe - formoteroli ja budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm oy - budesonidum,formoteroli fumaras dihydricus - inhalaatiojauhe - formoteroli ja budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

paranova oy - formoteroli fumaras dihydricus,budesonidum - inhalaatiojauhe - formoteroli ja budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm oy - formoteroli fumaras dihydricus,budesonidum - inhalaatiojauhe - formoteroli ja budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm oy - budesonidum,formoteroli fumaras dihydricus - inhalaatiojauhe - formoteroli ja budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

astrazeneca oy - budesonidum,formoteroli fumaras dihydricus - inhalaatiojauhe - 100 / 6 mikrog / annos - formoteroli ja budesonidi